Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
Abstract Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease. In a phase 2b dose-ranging study o...
Gardado en:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2021-01-01
|
| Series: | Arthritis Research & Therapy |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s13075-020-02379-6 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|